Proteogenomics Research Institute For Systems Medicine
- Assets
- $645.3k
- Revenue
- $6.3m
- Investments
- $0.0
- Employees
- 35
- Location
- San Diego, CA
- Founding
- 01/2011
- Data as of
- 06/2021
- EIN
- 80-0418281
Organization Overview
Proteogenomics Research Institute For Systems Medicine is located in San Diego, CA. The organization was established in 2011. According to its NTEE Classification (G05) the organization is classified as: Research Institutes & Public Policy Analysis, under the broad grouping of Voluntary Health Associations & Medical Disciplines and related organizations. As of 06/2021, Proteogenomics Research Institute For Systems Medicine employed 35 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Proteogenomics Research Institute For Systems Medicine is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 06/2021, Proteogenomics Research Institute For Systems Medicine generated $6.3m in total revenue. This organization has experienced exceptional growth, as over the past 6 years, it has increased revenue by an average of 15.1% each year . All expenses for the organization totaled $6.3m during the year ending 06/2021. While expenses have increased by 15.0% per year over the past 6 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2021
Describe the Organization's Mission:
Part 3 - Line 1
PROTEOGENOMICS RESEARCH INSTITUTE FOR SYSTEMS MEDICINE (PRISM) IS A NON-PROFIT BIOMEDICAL RESEARCH INSTITUTE FOCUSED ON THE DEVELOPMENT OF INNOVATIVE TREATMENTS FOR A WIDE SPECTRUM OF HUMAN DISEASES, INCLUDING CANCER.
Describe the Organization's Program Activity:
Part 3 - Line 4a
PRISM IS FOCUSED ON THE DEVELOPMENT OF INNOVATIVE TREATMENTS FOR A WIDE SPECTRUM OF HUMAN DISEASES, INCLUDING CANCER. PRISM EMPLOYS THE PRINCIPLES OF SYSTEMS SCIENCE, AN ORDERED AND INTERDISCIPLINARY APPROACH TO STUDY THE RELATIONSHIPS BETWEEN HEALTHY AND DISEASED TISSUES. PRISM'S STATE-OF-THE-ART FACILITIES COMBINE ADVANCED TECHNOLOGIES IN PROTEOMICS, GENOMICS AND IN VIVO IMAGING TO DISCOVER AND VALIDATE NOVEL THERAPEUTIC TARGETS. PRISM DEVELOPS NOVEL MOLECULES AND PROBES WHICH ALLOW DYNAMIC, NON-INVASIVE FUNCTIONAL IMAGING OF HEALTHY AND DISEASED TISSUE IN VIVO. THESE MOLECULES AND PROBES ARE THE CORE COMPONENT OF NEW THERAPIES, WHICH SPECIFICALLY TARGET DISEASED ORGANS WHILE SPARING NORMAL TISSUES AND CELLS. IN THIS WAY, PRISM IS DEVELOPING MORE EFFECTIVE, LESS TOXIC TREATMENTS THAT EXTEND LIFE AND PROVIDE A BETTER QUALITY OF LIFE FOR PATIENTS DIAGNOSED WITH CHRONIC AND LIFE-THREATENING DISEASES.
PRISM IS FOCUSED ON THE DEVELOPMENT OF INNOVATIVE TREATMENTS FOR A WIDE SPECTRUM OF HUMAN DISEASES, INCLUDING CANCER. PRISM EMPLOYS THE PRINCIPLES OF SYSTEMS SCIENCE, AN ORDERED AND INTERDISCIPLINARY APPROACH TO STUDY THE RELATIONSHIPS BETWEEN HEALTHY AND DISEASED TISSUES. PRISM'S STATE-OF-THE-ART FACILITIES COMBINE ADVANCED TECHNOLOGIES IN PROTEOMICS, GENOMICS AND IN VIVO IMAGING TO DISCOVER AND VALIDATE NOVEL THERAPEUTIC TARGETS. PRISM DEVELOPS NOVEL MOLECULES AND PROBES WHICH ALLOW DYNAMIC, NON-INVASIVE FUNCTIONAL IMAGING OF HEALTHY AND DISEASED TISSUE IN VIVO. THESE MOLECULES AND PROBES ARE THE CORE COMPONENT OF NEW THERAPIES, WHICH SPECIFICALLY TARGET DISEASED ORGANS WHILE SPARING NORMAL TISSUES AND CELLS. IN THIS WAY, PRISM IS DEVELOPING MORE EFFECTIVE, LESS TOXIC TREATMENTS THAT EXTEND LIFE AND PROVIDE A BETTER QUALITY OF LIFE FOR PATIENTS DIAGNOSED WITH CHRONIC AND LIFE-THREATENING DISEASES.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Jan E Schnitzer MD President & CEO | Officer | 40 | $198,807 |
Peggy Faix Dir Scientific Ops | 40 | $151,415 | |
Bogdan Olenyuk Professor | 40 | $137,193 | |
Michael Levin Dir Nanotechnology | 40 | $132,776 | |
Timothy Buss Sr Research Scient | 0 | $122,460 | |
L Jean Remmer Vice President | Officer | 32 | $116,704 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $6,338,383 |
| All other contributions, gifts, grants, and similar amounts not included above | $0 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $6,338,383 |
| Total Program Service Revenue | $0 |
| Investment income | $42 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $6,338,425 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $0 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $321,773 |
| Compensation of current officers, directors, key employees. | $152,904 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $1,951,023 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $629,715 |
| Payroll taxes | $186,535 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $0 |
| Fees for services: Accounting | $0 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $150,533 |
| Advertising and promotion | $0 |
| Office expenses | $34,277 |
| Information technology | $47,017 |
| Royalties | $0 |
| Occupancy | $832,084 |
| Travel | $4,477 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $0 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $11,655 |
| Insurance | $4,170 |
| All other expenses | $60,386 |
| Total functional expenses | $6,338,551 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $27,910 |
| Savings and temporary cash investments | $0 |
| Pledges and grants receivable | $530,544 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $5,830 |
| Net Land, buildings, and equipment | $37,879 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $43,167 |
| Total assets | $645,330 |
| Accounts payable and accrued expenses | $610,799 |
| Grants payable | $0 |
| Deferred revenue | $13,053 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $527,782 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $1,151,634 |
| Net assets without donor restrictions | -$506,304 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $645,330 |
Grants Recieved
Over the last fiscal year, we have identified 2 grants that Proteogenomics Research Institute For Systems Medicine has recieved totaling $40,000.
| Awarding Organization | Amount |
|---|---|
Susan G Komen Breast Cancer Foundation Dallas, TX PURPOSE: education | $20,000 |
Susan G Komen Breast Cancer Foundation Dallas, TX PURPOSE: education | $20,000 |
Peer Organizations
| Organization Name | Assets | Revenue |
|---|---|---|
Proteogenomics Research Institute For Systems Medicine San Diego, CA | $645,330 | $6,338,425 |
San Diego Spine Foundation San Diego, CA | $2,060,232 | $805,528 |
International Society For Peritoneal Dialysis Los Altos, CA | $2,376,793 | $909,377 |
Global Viral Menlo Park, CA | $1,078,579 | $704,425 |
T1international Usa Portland, OR | $443,314 | $917,203 |
Congress Medical Foundation Pasadena, CA | $611,186 | $503,833 |
Coalition For Reasonable Vaping Regulation San Francisco, CA | $136,490 | $0 |
Whittemore Peterson Institute Reno, NV | $937,641 | $290,630 |
Cardiovascular Institute Of Chicago Phoenix, AZ | $0 | $10,457 |
Rare Science Encinitas, CA | $24,930 | $0 |
Coral Caye Foundation La Habra, CA | $12,974 | $0 |
Arnew Foundation Walnut Creek, CA | $0 | $397 |